These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 11367984)
1. [Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis]. Wullen B; Mühlhöfer A; Zoller WG Z Gastroenterol; 2001 Apr; 39(4):335-7. PubMed ID: 11367984 [No Abstract] [Full Text] [Related]
2. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062 [TBL] [Abstract][Full Text] [Related]
3. Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis. Bresalier RS Gastroenterology; 2000 Dec; 119(6):1797-8. PubMed ID: 11113106 [No Abstract] [Full Text] [Related]
4. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626 [TBL] [Abstract][Full Text] [Related]
5. Arthritis drug approved for polyp prevention blazes trail for other prevention trials. Smigel K J Natl Cancer Inst; 2000 Feb; 92(4):297-9. PubMed ID: 10675374 [No Abstract] [Full Text] [Related]
6. Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis. Davies NM; Gudde TW; de Leeuw MA Expert Opin Pharmacother; 2001 Jan; 2(1):139-52. PubMed ID: 11336575 [TBL] [Abstract][Full Text] [Related]
7. Pain management in patients with osteoarthritis. Finucane TE JAMA; 2003 Jul; 290(1):36; author reply 36. PubMed ID: 12837705 [No Abstract] [Full Text] [Related]
8. [Improper use of selective COX-2 inhibitor NSAIDs]. Rocamora Batalla M; Vallano Ferraz A Aten Primaria; 2002 Feb; 29(2):122. PubMed ID: 11844430 [No Abstract] [Full Text] [Related]
9. Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality? Chau I; Cunningham D N Engl J Med; 2002 Apr; 346(14):1085-7. PubMed ID: 11932478 [No Abstract] [Full Text] [Related]
15. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective]. MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824 [No Abstract] [Full Text] [Related]
16. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). Wynn RL Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547 [No Abstract] [Full Text] [Related]
17. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. Hrachovec JB; Mora M JAMA; 2001 Nov; 286(19):2398; author reply 2399-400. PubMed ID: 11712924 [No Abstract] [Full Text] [Related]
18. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. Wright JM; Perry TL; Bassett KL; Chambers GK JAMA; 2001 Nov; 286(19):2398-400. PubMed ID: 11712925 [No Abstract] [Full Text] [Related]
19. Celecoxib: a COX-2 inhibitor. Andrews SA; Wallace CK; Davis RL Am J Manag Care; 1999 Apr; 5(4):511-8; quiz 522-4. PubMed ID: 10387389 [No Abstract] [Full Text] [Related]
20. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]